title: High-density lipoprotein inhibits the uptake of modified low- density lipoprotein and the expression of CD36 and FcgammaRI.
abstract: OBJECTIVE
  Modified low-density lipoprotein (mLDL), mainly upon oxidative and enzymatic modification, is the major atherogenic lipoprotein. Conversely, high-density lipoprotein (HDL) is considered antiatherogenic because of its ability to remove cholesterol. The aim of this work was to analyze both the influence of HDL on the uptake of mLDL and the expression of CD36 and Fcgamma I receptors on monocytic cell lines during cell differentiation.
  
  
  METHODS
  Uptake of fluorescein isothiocyanate (FITC)-conjugated LDL and FITC-conjugated mLDL, i.e., copper-oxidized LDL (oxLDL) or trypsin enzyme modified LDL (enzLDL), was analyzed, as well as the expression of CD36 and FcgammaRI in THP-1 and U937 cells, using flow cytometry.
  
  
  RESULTS
  HDL inhibited the uptake of mLDL, which varied in degree depending on the cell line or type of mLDL. Further, HDL rapidly decreased CD36 and FcgammaRI involved in the uptake of mLDL.
  
  
  CONCLUSIONS
  We demonstrate that modified LDL promotes specific LDL receptor-independent uptake by monocytic cell lines, and that the uptake of LDL and enzLDL is less than that of oxLDL. In this process, HDL diminishes the uptake of LDL or mLDL, which may involve the down-regulation of receptors (CD36 and Fcgamma I). This regulatory process represents another way by which HDL can be anti-atherogenic and it depends on the type of modification of LDL and the stage of differentiation of monocytes to macrophages.
authors.affiliation: Laboratório de Imunofisiopatologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil. mdias@usp.br
authors.forename: Márcia Dias Teixeira
authors.initials: MD
authors.lastname: Carvalho
authors.forename: Célia Maria Vieira
authors.initials: CM
authors.lastname: Vendrame
authors.forename: Daniel Francisco Jacon
authors.initials: DF
authors.lastname: Ketelhuth
authors.forename: Edite Hatsumi
authors.initials: EH
authors.lastname: Yamashiro-Kanashiro
authors.forename: Hiro
authors.initials: H
authors.lastname: Goto
authors.forename: Magnus
authors.initials: M
authors.lastname: Gidlund
mesh_terms: D018955:CD36 Antigens / Q000378:metabolism*; D002478:Cells, Cultured; D006801:Humans; D015151:Immunoblotting; D008075:Lipoproteins, HDL / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D017452:Receptors, IgG / Q000378:metabolism*; D018110:Receptors, Lipoprotein / Q000378:metabolism; D051116:Receptors, Scavenger / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000494:pharmacology
chemical_list: D018955:CD36 Antigens; C489017:FCGR1A protein, human; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D017452:Receptors, IgG; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; D017392:Thiobarbituric Acid Reactive Substances; C099252:oxidized low density lipoprotein